The United States will give up the vaccine patent, which will not affect China's free vaccination.
As early as February this year, China has reached vaccine export agreements with more than 2 countries, with a total order of more than 5 million doses, indicating that China has the strength of independent research and development and mass production, and the United States will give up the vaccine patent, which will not have much impact on the production, transportation and vaccination of vaccines in COVID-19.
We should be thankful for the timely screening and isolation at the beginning of the epidemic; Fortunately, we were born in China, and we were able to get vaccinated in time. We should also be glad to see the Chinese power behind it.
On the other hand, the vaccine situation in China:
After two doses of COVID-19 inactivated vaccine immunization program of China Bio-Beijing Company of Sinopharm Group, all the vaccinators in the vaccine group produced high titer antibodies, the positive conversion rate of neutralizing antibodies was 99.52%, and the protective effect of the vaccine against diseases caused by Covid-19 infection (Covid-19) was 79.34%.
under the national policy of free vaccination, the number of vaccinations in COVID-19, China has exceeded 2 million. After excluding the number of people who are not suitable for vaccination because of their health and age, nearly a quarter of people in China have been vaccinated with domestic vaccines. After such a large-scale vaccination, no serious adverse reactions have been found, so the safety factor is still very high.